DNA damage response company Artios Pharma Limited revealed on Monday the addition of Professor Rajesh Chopra PhD as a non-executive director (NED).
Recently, Dr Chopra has served as the corporate vice president of Translational Research at Celgene, where he led US and European teams of scientists in San Diego, San Francisco and Seville and clinicians from discovery to proof-of-concept clinical trials in oncology and immune/inflammatory diseases and stem cell therapies.
Previously, Dr Chopra was part of the oncology leadership team at AstraZeneca, where he established the Translational Medicine Group in Boston, Massachusetts.
Currently, Dr Chopra is head of the Division of Cancer Therapeutics and director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients